Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9632134 | 0.82 | LMNA (0.53) | SLC1A2ALDH1A1PKML3MBTL1 | |
| SCHEMBL3466786 | 0.77 | LMNA (0.66) | SMN1; SMN2SLC1A2ALDH1A1KCNN4KCNA5 | |
| SCHEMBL3468042 | 0.75 | KCNA5 (0.56) | SMN1; SMN2SLC1A2ALDH1A1KCNA5 | |
| SCHEMBL16967414 | 0.74 | KCNA5 (0.55) | SLC6A2SLC6A4SLC6A3SLC1A2ALDH1A1 | |
| SCHEMBL22207710 | 0.71 | ALDH1A1 (0.41) | CYP11B1CYP11B2CYP19A1SLC1A2ALDH1A1 | |
| SCHEMBL1533618 | 0.71 | SRC (0.58) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9398017 | 0.70 | ALDH1A1 (0.48) | CYP11B1CYP11B2CYP19A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7260309 | 0.70 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2684159 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31404936 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697604-B2 | Labeling agents for mass spectrometry comprising tertiary amines | ELECTROPHORETICS LIMITED (GB) | 2014-04-15 | — | — | US | disclosed |
| EP-1606623-B1 | LABELLING AGENTS FOR MASS SPECTROMETRY COMPRISING TERTIARY AMINES | ELECTROPHORETICS LTD (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-7371514-B2 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070023628-A1 | Labeling agents for mass spectrometry comprising tertiary amines | ELECTROPHORETICS LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20060229234-A1 | Peptide factor | STEVENSON ROBERT D | 2006-10-12 | — | — | US | disclosed |
| US-20060014210-A1 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060014293-A1 | Lock mass ions for use with derivatized peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1617223-A2 | Serial derivatization of peptides for \"de Novo\" sequencing using tandem mass spectrometry | Agilent Technologies, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1617224-A1 | De novo sequencing using tandem mass spectrometry | Agilent Technologies, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1606623-A2 | LABELLING AGENTS FOR MASS SPECTROMETRY COMPRISING TERTIARY AMINES | Xzillion GmbH & CO.KG (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040213772-A1 | Peptide factor | STEVENSON ROBERT DUNCAN | 2004-10-28 | — | — | US | disclosed |
| WO-2004086050-A2 | LABELLING AGENTS FOR MASS SPECTROMETRY COMPRISING TERTIARY AMINES | XZILLION GMBH & CO. KG (DE) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003104813-A2 | CHARACTERISING POLYPEPTIDES | XZILLION GMBH & CO. KG (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-6602519-B1 | Peptide factor used as replacement to steroid therapy; neutrophil migration stimulating activity; treating conditions associated with an inflammatory response of septic shock | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1094833-B1 | OXIDIZED THYMOSIN BETA 4 | UNIV GLASGOW (GB) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014210-A1 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | PTMS, DNPEP, SRMS | CYP11B1 3890/4885CYP11B2 4063/4885CYP19A1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.